NovImmune SA

45 articles with NovImmune SA

• Sobi Acquires Emapalumab and Related Assets

  6/12/2019

  The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded.

• Sobi and Novimmune Selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab)

  3/25/2019

  Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders for the 2019 Rare Impact Awards.

• New Emapalumab Data Presented at Transplantation and Cellular Therapy (TCT) Meeting Highlight Post-transplant Treatment Outcomes in Primary HLH

  2/26/2019

  Swedish Orphan Biovitrum AB and Novimmune SA announced the presentation of late-breaking data from the phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis at the 2019 Transplantation and Cellular Therapy Meetings, February 20-24 in Houston, Texas.

• Data Presented at ASH Support Emapalumab as an Innovative, Targeted Therapeutic Option for Primary HLH

  12/4/2018

  Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place 1-4 December 2018, in San Diego.

• Late-breaking Abstract at ASH Supports Evidence on Transformative First-ever Treatment in Primary HLH

  11/22/2018

  Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are pleased to announce that the abstract "Safety and efficacy of emapalumab in paediatric patients with primary hemophagocytic lymphohistiocytosis" was accepted as a late-breaking abstract at the 60th Annual Meeting of the American Society of Hematology in San Diego, California, 1-4 December 2018, for oral presentation.

• 

  Sobi's Recently-Acquired Gamifant Gets FDA Approval for Ultra-Rare Disease

  11/21/2018

  Sweden-based Sobi and Swiss-based Novimmune announced the U.S. approval of Gamifant (emapalumab-lzsg) to treat an ultra-rare disease in adults and children. Sobi’s U.S. offices are in Waltham, Mass.

• FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)

  11/20/2018

  Primary HLH is an ultra-rare syndrome of hyper-inflammation that usually occurs within the first year of life and can rapidly become lethal unless diagnosed and treated

• 

  With Q3 and 2018 Looking Good, Roche Abandons 8 Pipeline Products

  10/17/2018

  Overall, the Swiss-based Roche announced a group sales increase of 7 percent, with the Pharmaceuticals Division up 7 percent, largely driven by sales of Ocrevus, Perjeta, Alecensa and Tecentriq.

• Sobi™ strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune

  7/20/2018

  Swedish Orphan AB, an international biopharmaceutical company dedicated to rare diseases, and NovImmune SA have entered into an exclusive licence agreement for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis, developed by Novimmune SA, a privately-held, pre-commercial drug discovery and development company focused on rare inflammatory diseases, immune disorders and immuno-oncology.

• 

  TG Therapeutics and Novimmune Forge $185M Agreement

  6/20/2018

  TG Therapeutics and Novimmune SA struck a collaborative deal worth up to $185 million on the development and commercialization of a treatment for hematologic B-cell malignancies.

• Nordic Nanovector Strengthens Management Team With Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy

  6/1/2018

  Nordic Nanovector ASA (OSE: NANO) announces that Maureen Deehan, PhD, has been appointed as Head of Corporate Development and Strategy.

• Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement For NovImmune SA Bi-Specific Antibody

  7/18/2017

• NovImmune SA's NI-0501 Granted Breakthrough Therapy Designation By U.S. FDA For Treatment Of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH)

  3/16/2016

• NovImmune SA Completes CHF30 Million ($29.8 Million) Funding Round With Existing Shareholders

  1/12/2016

• Former Roche Exec Joins NovImmune SA as New CEO

  12/21/2015

• NovImmune SA Abstract Selected For The "Best Of ASH" At The 2015 Annual Meeting Of American Society of Hematology (ASH)

  12/16/2015

• NovImmune SA's Experimental Drug Selected For Oral Presentation At 2015 Annual Meeting Of American Society of Hematology

  12/2/2015

• NovImmune SA’s Experimental Drug Selected For Oral Presentation At 2015 Annual Meeting Of American Society of Hematology

  12/1/2015

• NovImmune SA's New Rheumatoid Arthritis Drug Clears Regulatory Hurdles

  11/3/2015

• NovImmune SA Announces Presentations At 2015 American College of Rheumatology Annual Meeting

  11/3/2015